Current status of the Arilvax; yellow fever vaccine
- 1 August 2004
- journal article
- Published by Taylor & Francis in Expert Review of Vaccines
- Vol. 3 (4) , 413-420
- https://doi.org/10.1586/14760584.3.4.413
Abstract
Yellow fever is a viral hemorrhagic fever that involves dysfunction of the liver and kidneys. There is no antiviral therapy available and vaccination is a major strategy in the control of this important public health problem. Yellow fever vaccine is a live attenuated vaccine, strain 17D, which is very safe and efficacious and induces long-term protective immunity in vaccinees. The vaccine is produced by six manufacturers worldwide, including Arilvax by Chiron vaccines (CA, USA) that is marketed in at least ten countries. Acambis (MA, USA) have acquired the rights to sell and market Arilvax in the USA, and have undertaken three clinical trials to obtain data for a Biological License Application that should proceed in 2005.Keywords
This publication has 19 references indexed in Scilit:
- Viscerotropic and neurotropic disease following vaccination with the 17D yellow fever vaccine, ARILVAX®Vaccine, 2004
- Yellow Fever Virus 17D Envelope and NS3 Proteins Are Major Targets of the Antiviral T Cell Response in MiceVirology, 2002
- Shortage of vaccines during a yellow fever outbreak in GuineaThe Lancet, 2001
- Advanced Age a Risk Factor for Illness Temporally Associated with Yellow Fever VaccinationEmerging Infectious Diseases, 2001
- Hepatitis and death following vaccination with 17D-204 yellow fever vaccineThe Lancet, 2001
- Serious adverse events associated with yellow fever 17DD vaccine in Brazil: a report of two casesThe Lancet, 2001
- Langat Virus M Protein Is Structurally Homologous to prMJournal of Virology, 2001
- Yellow Fever VaccinesBiologicals, 1997
- Yellow FeverJAMA, 1996
- Nucleotide Sequence of Yellow Fever Virus: Implications for Flavivirus Gene Expression and EvolutionScience, 1985